Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis

Aniruddha Agarwal; Rupesh Agrawal; Dhananjay Raje; Ilaria Testi; Sarakshi Mahajan; Dinesh Visva Gunasekeran; Kanika Aggarwal; Somasheila I. Murthy; Mark Westcott; Soon Phaik Chee; Peter Mccluskey; Su Ling Ho; Stephen Teoh; Luca Cimino; Jyotirmay Biswas; Shishir Narain; Manisha Agarwal; Padmamalini Mahendradas; Moncef Khairallah; Nicholas Jones; Ilknur Tugal-Tutkun; Kalpana Babu; Soumayava Basu; Ester Carreño; Richard Lee; Hassan Al-Dhibi; Bahram Bodaghi; Alessandro Invernizzi; Debra A. Goldstein; Carl P. Herbort; Talin Barisani-Asenbauer; Julio J. González-López; Sofia Androudi; Reema Bansal; Bruttendu Moharana; Simona Degli Esposti; Anastasia Tasiopoulou; Sengal Nadarajah; Mamta Agarwal; Sharanya Abraham; Ruchi Vala; Ramandeep Singh; Aman Sharma; Kusum Sharma; Manfred Zierhut; Onn Min Kon; Emmett T. Cunningham; John H. Kempen; Quan Dong Nguyen; Carlos Pavesio; Vishali Gupta

doi:10.1080/09273948.2020.1761401

Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis

Aniruddha Agarwal, Rupesh Agrawal, Dhananjay Raje, Ilaria Testi, Sarakshi Mahajan, Dinesh Visva Gunasekeran, Kanika Aggarwal, Somasheila I. Murthy, Mark Westcott, Soon Phaik Chee, Peter Mccluskey, Su Ling Ho, Stephen Teoh, Luca Cimino, Jyotirmay Biswas, Shishir Narain, Manisha Agarwal, Padmamalini Mahendradas, Moncef Khairallah, Nicholas JonesIlknur Tugal-Tutkun, Kalpana Babu, Soumayava Basu, Ester Carreño, Richard Lee, Hassan Al-Dhibi, Bahram Bodaghi, Alessandro Invernizzi, Debra A. Goldstein, Carl P. Herbort, Talin Barisani-Asenbauer, Julio J. González-López, Sofia Androudi, Reema Bansal, Bruttendu Moharana, Simona Degli Esposti, Anastasia Tasiopoulou, Sengal Nadarajah, Mamta Agarwal, Sharanya Abraham, Ruchi Vala, Ramandeep Singh, Aman Sharma, Kusum Sharma, Manfred Zierhut, Onn Min Kon, Emmett T. Cunningham, John H. Kempen, Quan Dong Nguyen, Carlos Pavesio, Vishali Gupta^*

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02). Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of “cure” may be a valuable clinical endpoint in trials for OTB.

Original language	English (US)
Pages (from-to)	1-9
Number of pages	9
Journal	Ocular Immunology and Inflammation
DOIs	https://doi.org/10.1080/09273948.2020.1761401
State	Published - 2020

Funding

The research was partially funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. This sponsor supported some of the research man-hours that were contributed by all our part-time collaborators from the Moorfields Eye Hospital that are salaried as Ophthalmology clinicians by the hospital. Debra A. Goldstein is supported by an unrestricted grant from Research to Prevent Blindness (RPB). Vishali Gupta is supported by grant from the Department of Biotechnology (DBT), India. Julio J GONZÁLEZ-LÓPEZ2 is supported by study grants from AbbVie, Allergan, and Angelini. Funders played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication.

Keywords

Collaborative Ocular Tuberculosis Study (COTS) group
Ocular tuberculosis
antitubercular therapy
cure
tubercular uveitis
tuberculous
uveitis

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/09273948.2020.1761401

Cite this

Agarwal, A., Agrawal, R., Raje, D., Testi, I., Mahajan, S., Gunasekeran, D. V., Aggarwal, K., Murthy, S. I., Westcott, M., Chee, S. P., Mccluskey, P., Ho, S. L., Teoh, S., Cimino, L., Biswas, J., Narain, S., Agarwal, M., Mahendradas, P., Khairallah, M., ... Gupta, V. (2020). Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis. Ocular Immunology and Inflammation, 1-9. https://doi.org/10.1080/09273948.2020.1761401

@article{5500fd947f1b40ffbae99fec5e391923,

title = "Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis",

abstract = "Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02). Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of “cure” may be a valuable clinical endpoint in trials for OTB.",

keywords = "Collaborative Ocular Tuberculosis Study (COTS) group, Ocular tuberculosis, antitubercular therapy, cure, tubercular uveitis, tuberculous, uveitis",

author = "Aniruddha Agarwal and Rupesh Agrawal and Dhananjay Raje and Ilaria Testi and Sarakshi Mahajan and Gunasekeran, {Dinesh Visva} and Kanika Aggarwal and Murthy, {Somasheila I.} and Mark Westcott and Chee, {Soon Phaik} and Peter Mccluskey and Ho, {Su Ling} and Stephen Teoh and Luca Cimino and Jyotirmay Biswas and Shishir Narain and Manisha Agarwal and Padmamalini Mahendradas and Moncef Khairallah and Nicholas Jones and Ilknur Tugal-Tutkun and Kalpana Babu and Soumayava Basu and Ester Carre{\~n}o and Richard Lee and Hassan Al-Dhibi and Bahram Bodaghi and Alessandro Invernizzi and Goldstein, {Debra A.} and Herbort, {Carl P.} and Talin Barisani-Asenbauer and Gonz{\'a}lez-L{\'o}pez, {Julio J.} and Sofia Androudi and Reema Bansal and Bruttendu Moharana and Esposti, {Simona Degli} and Anastasia Tasiopoulou and Sengal Nadarajah and Mamta Agarwal and Sharanya Abraham and Ruchi Vala and Ramandeep Singh and Aman Sharma and Kusum Sharma and Manfred Zierhut and Kon, {Onn Min} and Cunningham, {Emmett T.} and Kempen, {John H.} and Nguyen, {Quan Dong} and Carlos Pavesio and Vishali Gupta",

note = "Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2020",

doi = "10.1080/09273948.2020.1761401",

language = "English (US)",

pages = "1--9",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

}

Agarwal, A, Agrawal, R, Raje, D, Testi, I, Mahajan, S, Gunasekeran, DV, Aggarwal, K, Murthy, SI, Westcott, M, Chee, SP, Mccluskey, P, Ho, SL, Teoh, S, Cimino, L, Biswas, J, Narain, S, Agarwal, M, Mahendradas, P, Khairallah, M, Jones, N, Tugal-Tutkun, I, Babu, K, Basu, S, Carreño, E, Lee, R, Al-Dhibi, H, Bodaghi, B, Invernizzi, A, Goldstein, DA, Herbort, CP, Barisani-Asenbauer, T, González-López, JJ, Androudi, S, Bansal, R, Moharana, B, Esposti, SD, Tasiopoulou, A, Nadarajah, S, Agarwal, M, Abraham, S, Vala, R, Singh, R, Sharma, A, Sharma, K, Zierhut, M, Kon, OM, Cunningham, ET, Kempen, JH, Nguyen, QD, Pavesio, C & Gupta, V 2020, 'Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis', Ocular Immunology and Inflammation, pp. 1-9. https://doi.org/10.1080/09273948.2020.1761401

TY - JOUR

T1 - Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1

T2 - Defining the “Cure” in Ocular Tuberculosis

AU - Agarwal, Aniruddha

AU - Agrawal, Rupesh

AU - Raje, Dhananjay

AU - Testi, Ilaria

AU - Mahajan, Sarakshi

AU - Gunasekeran, Dinesh Visva

AU - Aggarwal, Kanika

AU - Murthy, Somasheila I.

AU - Westcott, Mark

AU - Chee, Soon Phaik

AU - Mccluskey, Peter

AU - Ho, Su Ling

AU - Teoh, Stephen

AU - Cimino, Luca

AU - Biswas, Jyotirmay

AU - Narain, Shishir

AU - Agarwal, Manisha

AU - Mahendradas, Padmamalini

AU - Khairallah, Moncef

AU - Jones, Nicholas

AU - Tugal-Tutkun, Ilknur

AU - Babu, Kalpana

AU - Basu, Soumayava

AU - Carreño, Ester

AU - Lee, Richard

AU - Al-Dhibi, Hassan

AU - Bodaghi, Bahram

AU - Invernizzi, Alessandro

AU - Goldstein, Debra A.

AU - Herbort, Carl P.

AU - Barisani-Asenbauer, Talin

AU - González-López, Julio J.

AU - Androudi, Sofia

AU - Bansal, Reema

AU - Moharana, Bruttendu

AU - Esposti, Simona Degli

AU - Tasiopoulou, Anastasia

AU - Nadarajah, Sengal

AU - Agarwal, Mamta

AU - Abraham, Sharanya

AU - Vala, Ruchi

AU - Singh, Ramandeep

AU - Sharma, Aman

AU - Sharma, Kusum

AU - Zierhut, Manfred

AU - Kon, Onn Min

AU - Cunningham, Emmett T.

AU - Kempen, John H.

AU - Nguyen, Quan Dong

AU - Pavesio, Carlos

AU - Gupta, Vishali

PY - 2020

Y1 - 2020

N2 - Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02). Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of “cure” may be a valuable clinical endpoint in trials for OTB.

AB - Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02). Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of “cure” may be a valuable clinical endpoint in trials for OTB.

KW - Collaborative Ocular Tuberculosis Study (COTS) group

KW - Ocular tuberculosis

KW - antitubercular therapy

KW - cure

KW - tubercular uveitis

KW - tuberculous

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85087522269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087522269&partnerID=8YFLogxK

U2 - 10.1080/09273948.2020.1761401

DO - 10.1080/09273948.2020.1761401

M3 - Article

C2 - 32589551

AN - SCOPUS:85087522269

SN - 0927-3948

SP - 1

EP - 9

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

ER -

Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the “Cure” in Ocular Tuberculosis

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this